logo-loader
CelLBxHealth PLC

CelLBxHealth PLC - Board changes

RNS Number : 4265O
CelLBxHealth PLC
12 January 2026
 

12 January 2026

 

CelLBxHealth plc (the "Company")

 

Board changes

 

Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect:

 

·      Peter Collins as Chief Executive Officer

·      Klaas de Boer as Non-Executive Director

·      Kim Oreskovic as Non-Executive Director

·      Benjamin Hart as Non-Executive Director

 

The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.

 

Separately Non-Executive Director, Joseph Eid will step down from the board, effective 31 January 2026.

 

Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and the non-executives to the board.   Their extensive expertise, combined with additional life sciences experience will significantly enhance the board's capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future."

 

For further information:

 

CelLBxHealth plc

Peter Collins, Chief Executive Officer

+44 (0) 1483 343434  

investor@CelLBxHealth.com

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

 

+44 (0) 20 7220 0500

 FTI Consulting

Simon Conway, Ciara Martin, Sam Purewal

+44 (0) 203 727 1000

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

About CelLBxHealth plc

 

CelLBxHealth plc is a leading CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

 

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.

 

 The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

 

For more information, visit https://cellbxhealth.com/.

 

AIM Rules Schedule 2 (g) information

 

The directorships and partnerships currently held by Peter Michael Collins, aged 67, and over the five years preceding the date of this announcement are as follows:

 

Current directorships

Previous directorships held in the past five years

 

Saga Diagnostics UK Limited

SAGA Diagnostics AB

Collins Biotech Consulting SRL

 

The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

Tsjukemar Ltd

General Fusion Inc

Xeros Technology Group plc

SmartKem Inc

Smartkem Ltd

Fashion for Good BV

Entrepreneurs Fund Management LLP

Entrepreneurs Fund Management Services Ltd

veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH)

Stichting Administratiekantoor Bellevue

 

 

 

The directorships and partnerships currently held by Benjamin Jacob Hart, aged 38, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

 

Applied Technology Partners LLC

 

The directorships and partnerships currently held by Kimberley Anne Oreskovic, aged 60, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

Innoviance Investments B.V.

Innoviance Consulting B.V.

 

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAXFFFAFKEFA
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

Gelion, CelLBxHealth, Ashtead Technology, Rainbow Rare Earths, Bradda Head...

Gelion PLC (AIM:GELN, OTC:GELNF) shares rose over 12% to 18p after it reported £9.6 million of pro forma cash and no debt. Releasing full-year results, it noted agreements with two major automakers, and the CEO says it’s moving from validation towards customer programmes and scale-up. Read...

4 weeks, 1 day ago

4 min read